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University of Edinburgh, Edinburgh, United Kingdom
The hypoxic ventilatory response (HVR) is markedly attenuated by AMPK-α1 deletion
conditional on the expression of Cre-recombinase in tyrosine hydroxylase (TH)
expressing cells, precipitating marked increases in apnea frequency and duration. It
was concluded that ventilatory dysfunction caused by AMPK deficiency was driven
by neurogenic mechanisms. However, TH is transiently expressed in other cell types
during development, and it is evident that central respiratory depression can also be
triggered by myogenic mechanisms that impact blood supply to the brain. We therefore
assessed the effect on the HVR and systemic arterial blood pressure of AMPK deletion in
vascular smooth muscles. There was no difference in minute ventilation during normoxia.
However, increases in minute ventilation during severe hypoxia (8% O2) were, if affected
at all, augmented by AMPK-α1 and AMPK-α2 deletion in smooth muscles; despite
the fact that hypoxia (8% O2) evoked falls in arterial SpO2 comparable with controls.
Surprisingly, these mice exhibited no difference in systolic, diastolic or mean arterial
blood pressure during normoxia or hypoxia. We conclude that neither AMPK-α1 nor
AMPK-α2 are required in smooth muscle for the regulation of systemic arterial blood
pressure during hypoxia, and that AMPK-α1 deficiency does not impact the HVR by
myogenic mechanisms.
Keywords: AMPK, hypoxia, ventilation, blood pressure, smooth muscle
INTRODUCTION
The AMP-activated protein kinase (AMPK) is a cellular energy sensor that maintains cell-
autonomous energy homeostasis. From its 2 α (catalytic), 2 β and 3 γ (regulatory) subunits
12 AMPK heterotrimers may be formed, each harboring different sensitivities to activation by
increases in cellular AMP and ADP, and the capacity to directly phosphorylate and thus regulate
different targets (Ross et al., 2016). AMPK is coupled to mitochondrial oxidative phosphorylation
by two discrete albeit cooperative pathways, involving liver kinase B1 (LKB1) and changes in
the cellular AMP:ATP and ADP:ATP ratios. Binding of AMP to the AMPK γ subunit increases
activity 10-fold by allosteric activation alone, while AMP or ADP binding delivers increases
in LKB1-dependent phosphorylation and reductions in dephosphorylation of Thr172 on the α
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subunit that confer 100-fold further activation. All of these effects
are inhibited by ATP (Gowans et al., 2013). LKB1 is, therefore,
the principal pathway for AMPK activation during metabolic
stresses such as hypoxia. However, there are alternative Ca2+-
dependent pathways to AMPK activation that are governed by the
calmodulin-dependent protein kinase CaMKK2, which delivers
increases in Thr172 phosphorylation and thus AMPK activation
independent of changes in cellular AM(D)P:ATP ratios.
Classically AMPK regulates cell-autonomous pathways of
energy supply by phosphorylating targets that switch off non-
essential anabolic processes that consume ATP and switch on
catabolic pathways that generate ATP, thereby compensating
for deficits in ATP supply or availability (Ross et al., 2016).
Recently, however, we demonstrated (Mahmoud et al., 2016)
that the role of AMPK in metabolic homeostasis is not limited
to such cell autonomous pathways, but extends to the hypoxic
ventilatory response (HVR) (Teppema and Dahan, 2010; Wilson
and Teppema, 2016) and thus O2 and energy (ATP) supply
to the body as a whole. In doing so AMPK acts to oppose
central respiratory depression during hypoxia and thus resists
hypoventilation and apnea.
However, the HVR could well be affected by AMPK deficiency
in cell systems other than catecholaminergic neurons due to
off-target AMPK deletion through “leakage” of Cre beyond
those cells targeted by the conditional deletion strategy we
employed. This possibility is highlighted by the fact that
transient developmental expression of TH occurs in disparate
cell groups that do not express TH in the adult (Lindeberg
et al., 2004), including, for example, a subset of heart wall cells.
Therefore, there remains the possibility that AMPK deficiency
might somehow affect ventilatory control mechanisms through
myogenic rather than neurogenic mechanisms. This is evident
from the fact that systemic arteries dilate in response to tissue
hypoxemia in order to match local perfusion to local metabolism
(Roy and Sherrington, 1890), and evidence suggests a role for
AMPK in this response (Goirand et al., 2007; Schneider et al.,
2015). With “leakage” of Cre, off-target deletion of AMPK
in arterial myocytes could attenuate arterial dilation and thus
impact O2 supply to the brain during hypoxia and the HVR. This
possibility is highlighted by the fact that respiratory failure can
be triggered through the Cushing reflex consequent to marked
increases in blood pressure (Guyenet, 2000; Paton et al., 2009).
We therefore assessed the impact of AMPK deficiency in
smooth muscles on blood pressure control and the HVR. Our
data show that AMPK does not contribute to the HVR or blood
pressure control during hypoxia through myogenic mechanisms.
MATERIALS AND METHODS
Experiments were performed in accordance with the regulations
of the United Kingdom Animals (Scientific Procedures) Act of
1986. All studies and breeding were approved by the University
of Edinburgh and performed under UK Home Office project
licenses. Both male and female mice were used, and all were
on a C57/Bl6 background. Numbers of mice (≥3 per measure)
used are indicated for each experiment. Global, dual knockout
of the genes encoding AMPK-α1 (Prkaa1) and AMPK-α2
(Prkaa2) is embryonic lethal. We therefore employed conditional
deletion of the genes for the AMPK-α1 or AMPK-α2 subunits,
using mice in which the sequence encoding the catalytic
site of either or both of the α subunits was flanked by loxP
sequences (Lantier et al., 2014). To direct AMPK deletion to
cells of the smooth muscle lineage, these were crossed with
mice in which Cre recombinase was under the control of
the transgelin (smooth muscle protein 22α) promoter (The
Jackson Laboratory, Bar Harbor, ME, United States [stock
number 017491, Tg(Tagln-cre)1Her/J in C57BL/6:129SJL
background]). The presence of wild-type or floxed alleles and
CRE recombinase were detected by PCR. We used four primers
for Cre (Transgene 5′-GCGGTCTGGCAGTAAAAACTATC-
3′ and 5′-GTGAAACAGCATTGCTGTCACTT-3′; internal
positive control 5′-CTAGGCCACAGAATTGAAAGATCT-3′
and 5′-GTAGGTGGAATTTCTAGCATCATCC-3′; expected
size WT = 324 bp, Cre = 100 bp). Two primers were
used for each AMPK catalytic subunit: α1-forward 5′-
TATTGCTGCCATTAGGCTAC-3′, α1-reverse: 5′-GACCTGAC
AGAATAGGATATGCCCAACCTC-3′ (WT = 588 bp,
Floxed = 682 bp); α2-forward 5′-GCTTAGCACGTTACCC
TGGATGG-3′, α2-reverse: 5′-GTTATCAGCCCAACTAATT
ACAC-3′ (WT = 204 bp, Floxed = 250 bp). 10 µl samples were
run on 2% agarose gels with 0.01% v/v SYBR R©Safe DNA Gel
Stain (Invitrogen) in TBE buffer against a 100 bp DNA ladder
(GeneRulerTM, Fermentas) using a Model 200/2.0 Power Supply
(Bio-Rad). Gels were imaged using a Genius Bio Imaging System
and GeneSnap software (Syngene).
End-Point and Quantitative RT-PCR
For qPCR analysis, 2 µl of cDNA in RNase free water was made
up to 20 µl with 10 µl FastStart Universal SYBR Green Master
(ROX, Roche), 6.4 µl Ultra Pure Water (SIGMA) and forward
and reverse primers for AMPK-α1 and AMPK-α2. The sample
was then centrifuged and 20 µl added to a MicroAmpTM Fast
Optical 96-Well Reaction Plate (Greiner bio-one), the reaction
plate sealed with an optical adhesive cover (Applied Biosystems)
and the plate centrifuged. The reaction was then run on a
sequence detection system (Applied Biosystems) using AmpliTaq
Fast DNA Polymerase, with a 2 min initial step at 50◦C, followed
by a 10 min step at 95◦C, then 40x 15 s steps at 95◦C. This was
followed by a dissociation stage with 15 s at 95◦C, 20 s at 60◦C,
and 15 s at 95◦C. Negative controls included control cell aspirants
for which no reverse transcriptase was added, and aspiration of
extracellular medium and PCR controls. None of the controls
produced any detectable amplicon, ruling out genomic or other
contamination.
Plethysmography
As described previously (Mahmoud et al., 2016), we used
a whole-body unrestrained plethysmograph, incorporating a
HalcyonTM low noise pneumatochograph (Buxco Research
Systems, United Kingdom) coupled to FinePointe acquisition
and analysis software (Data Science International, United States).
Following acclimation and baseline measurements (awake but
quiet, undisturbed periods of breathing) under normoxia (room
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air), mice were exposed to hypoxia (8% O2, with 0.05%
CO2, balanced with N2) for 10 min. The FinePointe software
automatically calculated the respiratory parameters assessed after
application of exclusion criteria due to non-ventilatory artifacts
(movement, sniffing, etc.). Data were acquired as 2 s averages
and 2 to 4 data points of undisturbed breathing were selected for
each time point of the HVR. Apneas were defined as a period of
cessation of breathing that was greater than the average duration,
including interval, of two successive breaths (∼600 ms) of control
mice during normoxia with a detection threshold of 0.25 mmHg
(SD of noise).
Blood Pressure Measurements
Blood pressure was recorded using a CODA non-invasive blood
pressure system (Kent Scientific, United States). Following five
consecutive days of habituation “training,” mice were restrained
using a pre-warmed mouse holder and placed on a warming
platform (Kent Scientific, United States). Resting blood pressure
was measured 32 times per session and only stable readings
throughout each session were considered for analysis. On
separate days hypoxic blood pressure was measured using the
following protocol: 13 cycles of normoxia, 16 cycles of hypoxia
(8% O2, with 0.05% CO2, balanced with N2; approximately
10 min) and finally eight cycles of recovery (approximately
5 min). Hypoxic gas originating from a pre-mixed gas cylinder
(BOC, United Kingdom) was delivered at a flow rate of 2 L/min
via a head cone that inserts into the mouse holder.
Measurement of Arterial Oxygen
Saturation and Heart Rate
Arterial SpO2 measurements of mice were obtained using the
MouseSTATTM Pulse Oximeter (Kent Scientific, United States)
and an infrared Y-style tail sensor at a sampling rate of 0.5 Hz.
As above, mice were restrained using a pre-warmed mouse
holder and placed on a warming platform (Kent Scientific,
United States). Following 5 min of acclimation, baseline SpO2
and heart rates were measured for 2 min immediately preceding a
10-min period of hypoxia (8% O2, with 0.05% CO2, balanced with
N2), followed by 3–5 min of recovery. Hypoxic gas originating
from a pre-mixed gas cylinder (BOC, United Kingdom) was
delivered at a flow rate of 2 L/min via a head cone that inserts
into the mouse holder.
Statistical Analysis
Statistical comparison was completed using GraphPad Prism
6 for the following: plethysmography, two-way ANOVA with
Bonferroni multiple comparison’s test; blood pressure, one-
way ANOVA with Bonferroni multiple comparison’s test, SpO2,
two-way ANOVA with Bonferroni multiple comparison’s test.
p< 0.05 was considered significant.
RESULTS
We investigated the possibility that AMPK-α1 or AMPK-α2
subunits might support myogenic responses to hypoxia and thus
impact the HVR and blood pressure control. To achieve this
goal we developed mice with conditional deletion in smooth
muscles of the gene encoding AMPK-α1 (Prkaa1) and AMPK-
α2 (Prkaa2), respectively. Critical exons of the AMPK-α1 and
-α2 subunit genes were flanked by loxP sequences (Lantier
et al., 2014), and each floxed mouse line was crossed with mice
expressing Cre recombinase under the control of the transgelin
promoter (smooth muscle protein 22α) (El-Bizri et al., 2008).
Previous studies have shown that transgelin-Cre mice do not
exhibit Cre expression in endothelial cells, and therefore provide
for selective gene deletion in smooth muscle versus endothelial
cells (Supplementary Figure S1). It should be noted, however,
that transient developmental expression of transgelin has been
observed in atrial and ventricular myocytes. Consequently,
genomic recombination will also occur in these cells despite the
fact that they do not express transgelin in the adult (El-Bizri et al.,
2008). Therefore, while imperfect, the use of transgelin-Cre mice
provided us with the necessary level of specificity to determine the
role of smooth muscle AMPK in myogenic responses to hypoxia
that impact the HVR and blood pressure control.
FIGURE 1 | The hypoxic ventilatory response (HVR) is not attenuated by conditional deletion of AMPK-α1 and AMPK-α2 subunits in smooth muscles. Bar charts
show mean ± SEM for changes in (A) respiratory frequency, (B) tidal volume, and (C) minute ventilation for AMPK-α1/α2 floxed mice (Flx; black, n = 12), and for
mice with AMPK-α1 (n = 4; magenta) and AMPK-α2 (n = 4; blue) deletion in smooth muscles (transgelin expressing cells) during the peak of the Augmenting phase
(A), after approximately 100s of Roll Off (RO) and the plateau of the Sustained Phase (SP) of the response to hypoxia; ∗p < 0.05.
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The Hypoxic Ventilatory Response Is Not
Attenuated by AMPK-α1 or AMPK-α2
Deficiency in Smooth Muscles
Mice with conditional deletion of AMPK-α1 or AMPK-α2
subunits in smooth muscles exhibited no obvious phenotype
and no ventilatory dysfunction or deficiency was evident
during normoxia (not shown). Most significantly in the context
of the present investigation, we identified no significant
attenuation of the HVR relative to controls (AMPK-
α1/α2 floxed; Figure 1 and Supplementary Figure S2A).
That said, we did observe subtle differences between
genotypes.
For smooth muscle AMPK-α1 knockouts alone, there
appeared to be an insignificant yet noticeable lowering, relative
to controls, of breathing frequency during hypoxia following
Roll-Off (≈100 s; −13 ± 4 and 11 ± 4%, respectively) that
was maintained for the duration of the Sustained Phase (2–
5 min; −2 ± 7 and 12 ± 4%, respectively) of the HVR
(Figure 1A). By contrast, in both AMPK-α1 and AMPK-α2
knockouts larger increases in tidal volume were observed when
compared to controls (Figure 1B and Table 1), which reached
significance for AMPK-α1 knockouts, but only at the peak of
Roll-Off (17 ± 6 versus −1 ± 3%, respectively; p < 0.05).
Increases in minute ventilation during hypoxia also showed a
tendency to be greater for AMPK-α1 and AMPK-α2 knockouts
than for controls (AMPK-α1/α2 floxed). However this only
reached significance during the initial Augmenting Phase of
the HVR (Figure 1C; p < 0.05), which primarily results from
increases in carotid body afferent input responses (Day and
Wilson, 2007; Teppema and Dahan, 2010; Wilson and Teppema,
2016).
Perhaps most striking was the fact that deletion of neither the
AMPK-α1 nor AMPK-α2 catalytic subunits in smooth muscles
had any discernible effect on hypoxia-evoked apneas (Figure 2,
Table 1, and Supplementary Figure S2B), when compared to
controls (AMPK-α1/α2 floxed). This is evident from the fact that
there was no difference in either the apnea frequency (Figure 2A),
duration (Figure 2B), or apnea duration index (Figure 2C)
in mice lacking AMPK-α1 or AMPK-α2 subunits in smooth
muscles.
The aforementioned findings are in complete contrast
to our observations on mice with AMPK-α1 deletion in
catecholaminergic neurons (driven by TH-Cre) which exhibited
marked attenuation of the HVR and pronounced increases in
apnea frequency, duration and apnea duration index (Mahmoud
et al., 2016).
FIGURE 2 | Deletion of AMPK-α1 and AMPK-α2 subunits in smooth muscles does not affect apnea frequency or duration during hypoxia. Bar charts show
mean ± SEM for the (A) apneic index (per minute), (B) apnea duration, and (C) apnea duration index (frequency × duration) of AMPK-α1/α2 floxed mice (Flx; black,
n = 12), and for mice with AMPK-α1 (n = 4; magenta) and AMPK-α2 (n = 4; blue) deletion in smooth muscles (transgelin expressing cells).
TABLE 1 | Means ± SEM of percentage changes in breathing frequency, tidal volume, and minute ventilation and values for apnea frequency, apnea duration and apnea
duration index during exposures to hypoxia (8%O2) across all genotypes.
Genotype Frequency Tidal volume Minute ventilation Apnea frequency (min−1) Apnea duration (ms) Apnea duration index
AMPK-α1/α2 floxed A 61 ± 7% A -3 ± 2% A 53 ± 6% 3.0 ± 0.5 936 ± 40 2.9 ± 0.5
RO 11 ± 4% RO -1 ± 3% RO 8 ± 6%
SP 12 ± 4% SP -2 ± 3% SP 8 ± 5%
SM AMPK-α1 knockouts A 62 ± 4% A 12 ± 1% A 79 ± 7% 3.4 ± 1 1021 ± 86 3.4 ± 1
RO -13 ± 4% RO 17 ± 6% RO -1 ± 4%
SP -2 ± 7% SP 22 ± 5% SP 16 ± 5%
SM AMPK-α2 knockouts A 68 ± 6% A 10 ± 2% A 84 ± 7% 2.4 ± 0.9 900 ± 90 2.3 ± 1
RO 7 ± 5% RO 12 ± 2% RO 19 ± 6%
SP 20 ± 4% SP 11 ± 1% SP 33 ± 4%
A, Augmenting Phase; RO, Roll-Off; SP, Sustained Phase.
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FIGURE 3 | Deletion of AMPK-α1 and AMPK-α2 subunits in smooth muscles has no effect on systemic arterial blood pressure during normoxia or hypoxia. (A) Bar
charts show (mean ± SEM) the mean, systolic and diastolic blood pressure of control mice [AMPK-α1/α2 floxed (Flx); n = 4; black] and mice with AMPK-α1 (n = 4;
magenta) and AMPK-α2 (n = 4; blue) deletion in smooth muscles (transgelin expressing cells). (B) Bar charts show the same measures of blood pressure during
normoxia (N), after 10 min to hypoxia (H; 8% O2) and following recovery to normoxia (R). (C) Bar charts show the percentage change in blood pressure during
hypoxia.
Cardiovascular Responses to Hypoxia
Remain Unaltered Following Deletion of
AMPK-α1 and AMPK-α2 in Smooth
Muscle Cells
We next assessed the effect of AMPK deficiency on cardiovascular
function during hypoxia by monitoring systemic blood pressure
during hypoxia. Deleting either AMPK-α1 or AMPK-α2
subunits in smooth muscle cells had little or no effect
on resting blood pressure (Figure 3A and Supplementary
Figure S2C). Furthermore neither smooth muscle AMPK-α1 nor
-α2 deficiency affected hypoxia-evoked falls in systemic blood
pressure in mice (Figures 3B,C, Table 2, and Supplementary
Figures S2Cii,iii), which were comparable to the range of
responses reported previously (Campen et al., 2005; Mahmoud
et al., 2016).
That comparable levels of arterial hypoxia were achieved in
all mice was confirmed by pulse oximetry, which demonstrated
significant and similar falls in SpO2 for all genotypes (Figure 4
and Supplementary Figure S2D, p < 0.0001). Moreover there
was no difference with respect to post-hypoxic recovery of arterial
SpO2 upon return to room air.
DISCUSSION
The present investigation demonstrates that the HVR is,
if anything, slightly augmented rather than attenuated by
AMPK-α1 or AMPK-α2 deficiency in smooth muscles (driven
by transgelin-Cre). This outcome is in marked contrast to
our previously reported finding that AMPK-α1 deficiency
in catecholaminergic neurons (driven by TH-Cre) markedly
attenuates the HVR and precipitates hypoventilation and apnea
during hypoxia (Mahmoud et al., 2016). Therefore, outcomes
are consistent with our previously proposed model of central
oxygen-sensing by catecholaminergic neurons of the brainstem
respiratory network. Briefly, we proposed that these neurons
deliver increases in respiratory drive during hypoxia in a
manner supported by AMPK heterotrimers incorporating the
catalytic α1 subunit, the activity of which we hypothesized
to be determined by integration of local hypoxic stress at
the brainstem with carotid body afferent input responses
that provide an index of peripheral hypoxia. Notably, natural
selection in high-altitude (Andean) populations has led to
single nucleotide polymorphisms in PRKAA1 (Bigham et al.,
2014).
FIGURE 4 | Comparable falls in arterial oxygen saturation were evoked in all genotypes during hypoxia. (A) Bar charts show mean ± SEM for the arterial oxygen
saturation (SpO2) during normoxia, after 10 min of hypoxia (8% O2) and following recovery to normoxia. (B) Percentage change in SpO2. AMPK-α1/α2 floxed (Flx;
black, n = 3), smooth muscle AMPK-α1 KO (magenta, n = 4) and smooth muscle AMPK-α2 KO (blue, n = 4) mice; ∗∗∗∗p < 0.001.
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TABLE 2 | Means ± SEM of values obtained by tail cuff blood pressure measurements and percentage changes in arterial SpO2 before, during, and after exposures to
hypoxia (8%O2) across all genotypes.
Genotype Resting BP (mmHg) Mean BP (mmHg) Sys BP (mmHg) Dias BP (mmHg) SpO2
AMPK-α1/α2 floxed M 112 ± 6 N 104 ± 3 N 123 ± 4 N 95 ± 3 N 89 ± 5%
Sys 131 ± 7 H 94 ± 3.5 H 116 ± 3.5 H 84 ± 4 H 69 ± 5%
Dias 103 ± 6 R 100 ± 2 R 121 ± 1 R 91 ± 2 R 92 ± 2%
AMPK-α1 knockouts M 101 ± 4 N 108 ± 8 N 132 ± 7.5 N 97 ± 8 N 96 ± 2%
Sys 126 ± 3 H 94 ± 5 H 123 ± 5 H 79 ± 6 H 75 ± 4%
Dias 89 ± 4 R 89 ± 12 R 133 ± 7 R 87 ± 7.5 R 94 ± 1%
AMPK-α2 knockouts M 96 ± 6 N 91 ± 12 N111 ± 13 N 81 ± 11 N 97 ± 0.5%
Sys 117 ± 8 H 77 ± 7 H 102 ± 9.5 H 66 ± 6.5 H 71 ± 3%
Dias 86 ± 5 R 102 ± 7 R 112 ± 13 R 79 ± 12 R 92 ± 2%
M, mean blood pressure; Sys, systolic blood pressure; Dias, diastolic blood pressure; N, normoxia (room air); H, hypoxia (8% O2); R, recovery (room air).
The significance of our present findings lies in the fact
that reduced cerebral arterial dilation could affect O2 supply
to the brain during hypoxia and thus the HVR through
consequent respiratory depression, because the activity of
brainstem respiratory networks is ultimately reliant on O2
delivery via the vasculature that could be modulated systemically
and locally through myogenic responses. Respiratory failure
may also be triggered through the Cushing reflex consequent
to increases in blood pressure (Guyenet, 2000; Paton et al.,
2009), which would be exacerbated by block of arterial dilation
consequent to AMPK deletion in arterial myocytes. Such system-
specific responses could well be affected by a number of
mechanisms through which AMPK has been proposed to regulate
myocyte function, rendering outcomes susceptible to off-target
AMPK deletion due to “leakage” of Cre beyond those cells
targeted by conditional deletion strategies. This was a distinct
possibility, given that transient developmental expression of TH
occurs in disparate cell groups that do not express TH in the adult
(Lindeberg et al., 2004), including, for example, a subset of heart
wall cells.
The outcomes of our present investigation indicate that
while AMPK has been shown to mediate ex vivo arterial
dilation in some circumstances (Goirand et al., 2007; Schneider
et al., 2015), neither the expression of AMPK-α1 nor AMPK-
α2 catalytic subunits in smooth muscles is a pre-requisite
for in vivo arterial dilation during hypoxia sufficient enough
to impact systemic arterial blood pressures. This is evident
because we observed little or no difference in peripheral
hypoxic vasodilation between genotypes tested here. Moreover,
systemic arterial pressures during normoxia and hypoxia were
within the typical range previously reported for wild-type mice
(Campen et al., 2004). Our findings do not, however, rule
out a role for AMPK in maintaining resting vascular tone
locally, or in governing organ-/tissue-specific perfusion and
oxygen supply. Indeed, studies on other vascular beds have
already revealed that AMPK might adjust local perfusion during
hypoxia. For example, AMPK may mediate hypoxic pulmonary
vasoconstriction (Evans et al., 2005, 2006; Evans, 2006), and thus
assist ventilation-perfusion matching by diverting blood from
oxygen deprived to oxygen rich areas of the lung (Bradford
and Dean, 1894; von Euler and Liljestrand, 1946). Furthermore,
evidence suggests that AMPK supports dilation of systemic
arteries, such as the aorta and mesenteric arteries, at the
level of smooth muscles that may counter tissue hypoxemia
(Schneider et al., 2015; Moral-Sanz et al., 2016). Accordingly,
AMPK has also been implicated in the regulation of uterine
artery reactivity during hypoxia (Skeffington et al., 2015), perhaps
linking maternal metabolic and cardiovascular responses during
pregnancy and governing oxygen and nutrient supply to the
fetus.
The mechanisms involved in systemic arterial dilation
during hypoxia include AMPK-dependent activation of
SERCA and BKCa channels in systemic arterial myocytes
(Schneider et al., 2015), while AMPK exerts its effects on
pulmonary arterial smooth muscle cells, at least in part,
through direct phosphorylation and inhibition of the voltage-
gated potassium channel KV1.5 (Moral-Sanz et al., 2016).
Significant to the context of our study, KV1.5 availability has
been proposed to impact cerebral myogenic responses (Koide
et al., 2018), which could equally well be affected by loss of
capacity for AMPK-dependent activation of SERCA and BKCa
channels. Either way, our data argue strongly against the
possibility that the HVR is influenced by AMPK-dependent
mechanisms within smooth muscles that might affect local
myogenic responses, irrespective of the tissue- and circulation-
specific function they might impact. Nevertheless, it would be
interesting to determine whether AMPK contributes to local
autoregulatory mechanisms in the cerebral vasculature during
hypoxia, even though we find no evidence of a significant
contribution to the HVR or peripheral control of systemic
blood pressures, which was the focus of this investigation.
That said, we cannot rule out the possibility that the outcome
of our previous studies using TH-Cre driven AMPK deletion
might have been affected through off-target effects at the
level of the vascular endothelium, because the conditional
deletion strategy used here does not produce Cre expression
in endothelial cells (El-Bizri et al., 2008). However, this seems
unlikely given the outcomes of our present investigation.
Therefore, hypoxic ventilatory dysfunction precipitated
by AMPK-α1 deletion conditional on Cre expression in
catecholaminergic neurons does not result, in whole or in part,
from AMPK-α1 or AMPK-α2 deficiency in smooth muscles
Frontiers in Physiology | www.frontiersin.org 6 June 2018 | Volume 9 | Article 655
fphys-09-00655 June 4, 2018 Time: 14:18 # 7
MacMillan and Evans AMPK Blood Pressure and the HVR
and consequent changes in systemic arterial blood pressure
during hypoxia.
In short, AMPK likely supports the HVR through neurogenic
but not myogenic mechanisms as previously proposed, by
supporting increased respiratory drive (Mahmoud et al., 2016)
and perhaps functional hyperemia (Bucher et al., 2014), each of
which may be coordinated by catecholaminergic neurons of the
brainstem cardiorespiratory network.
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FIGURE S1 | End-point RT-PCR confirms AMPK deletion. End-point RT-PCR
amplicons for transgelin and the catalytic α1 and α2 subunits of AMPK from lungs
(right) and primary cultures of pulmonary arterial smooth muscle cells (PASMC,
left) obtained from transgelin-Cre, C57BL6 (WT), AMPK-α1 and AMPK-α2
knockout mice.
FIGURE S2 | Deletion of AMPK-α1 or AMPK-α2 subunits in smooth muscles
does not attenuate the HVR and has no effect on either apnea duration index or
systemic arterial blood pressures during hypoxia. Box plots show the median
(solid line), 25th to 75th percentiles (boxes), mean (+) and whiskers according to
Tukey’s method for: the % change of the ventilatory components of (Ai) breathing
frequency, (Aii) tidal volume, and (Aiii) minute ventilation during the initial
Augmenting Phase (A), the Roll-Off (RO), and the Sustained Phase (SP) of the
hypoxic ventilatory response; (Bi) the apneic index (per minute), (Bii) apnea
durations (in msec) and (Biii) apnea duration index (frequency x duration); Mean,
Systolic and Diastolic blood pressures (in mmHg) measured (Ci) at rest, (Cii)
before, during, and after a 10 min hypoxic challenge, and (Ciii) as % change
during hypoxia; arterial oxygen saturation (in %) during (Di) normoxia, 10 min
hypoxia, and recovery, and (Dii) as % change during hypoxia and recovery.
∗p < 0.05; ∗∗∗p < 0.001.
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